Shamburg News · 8-K filed Oct 20, 2026, 5:04 PM EDT

Surrozen Closes Second Tranche of March 2025 Private Placement for $95.1 Million

SRZN · Surrozen, Inc./DE

  • Financing
  • Materiality: high

Surrozen, Inc. completed the second and final tranche closing of its March 2025 private placement on October 20, 2026, with institutional and accredited investors, for aggregate gross proceeds of approximately $95.1 million before placement agent fees and expenses. The closing followed FDA clearance of the Investigational New Drug application for SZN-8141 announced October 2, 2026, and included 5,741,605 common shares at $11.60 per share, pre-funded warrants for 2,456,500 shares, and Series E common warrants for 4,099,052 shares with an exercise price of $11.54. The company agreed to file a resale registration statement within 30 calendar days of the closing.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 3.02, 9.01, accession 0001193125-26-426828.

Written from the filing by Shamburg Markets. Figures are as reported by the company.